Skip to main content
CRMD
NASDAQ Life Sciences

CorMedix Pays $145M Cash Plus Stock for Heron Assets, Adds Four Commercial Drugs

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
9
Price
$5.5
Mkt Cap
$414.664M
52W Low
$5.1
52W High
$13.02
52W Position info
7.8% above low
Off High info
58% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

CRMD is trading near its 52-week low of $5.1 (7.8% above the low).

Summary

CorMedix signed a definitive agreement to buy substantially all of Heron Therapeutics' assets for $145M in cash plus 14,583,333 CRMD shares — about $77.6M of stock at the $5.32 close on Nov 6, for roughly $222.6M upfront. Heron can also collect up to $55M in earn-outs tied to 2028 ZYNRELEF sales and a 5% royalty on combined CINVANTI, SUSTOL and licensed-product sales above $25M in 2027-2029. The deal hands CorMedix four commercial products (ZYNRELEF, APONVIE, CINVANTI, SUSTOL) that fit its hospital and surgery-center sales channel, and management pegs $45-$60M of annual cost synergies by year-end 2027. CorMedix is funding the cash piece with a $75M draw on a new $150M Pharmakon term loan, with a second $75M tranche available through June 2028 — non-dilutive debt, but it adds leverage on top of the share issuance. Pro forma 2026 revenue is guided to $465-$490M versus the $325-$355M standalone range, and the acquired assets are expected to add $125-$150M in 2027. Closing is targeted for Q1 2027, subject to Heron stockholder approval and HSR clearance; holders of about 22% of Heron, including Rubric, have already agreed to vote yes. Heron will exit operation of its current biotechnology business and other historical operations but does not intend to liquidate and will remain a publicly traded company, repaying its credit facility and retaining a significant position in CorMedix common stock plus rights to the earn-out and royalty payments, along with significant federal and state net operating loss carryforwards of about $2.3B as of Sept 30. Heron's board will evaluate various strategic transactions for use of the transaction proceeds, including acquiring or investing in further businesses or assets, which may or may not be pharmaceutical or biotechnology businesses or assets. CorMedix reports Q3 results Nov 12 and hosts a call on the deal today at 4:30 p.m. ET.

At the time of this announcement, CRMD was trading at $5.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $414.7M. The 52-week trading range was $5.10 to $13.02. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CRMD - Latest Insights

CRMD
Nov 02, 2026, 7:39 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $5.55 info
Change: +$0.0537 (+0.98%) info
Market Cap: $414.664M info
CRMD
Nov 02, 2026, 7:32 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.62
Real-time Price: $5.55 info
Change: -$0.0618 (-1%) info
Market Cap: $414.664M info
CRMD
Oct 19, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.45
Real-time Price: $5.55 info
Change: -$1.89 (-25%) info
Market Cap: $414.664M info
CRMD
Aug 13, 2026, 8:07 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.65
Real-time Price: $5.55 info
Change: -$2.10 (-27%) info
Market Cap: $414.664M info
CRMD
Aug 13, 2026, 7:44 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.65
Real-time Price: $5.55 info
Change: -$2.10 (-27%) info
Market Cap: $414.664M info